Citius Oncology, Inc. (CTOR)vsTeva Pharma Industries Ltd ADR (TEVA)
CTOR
Citius Oncology, Inc.
$0.52
-5.46%
HEALTHCARE · Cap: $58.59M
TEVA
Teva Pharma Industries Ltd ADR
$43.24
+0.95%
HEALTHCARE · Cap: $50.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 242398% more annual revenue ($17.23B vs $7.11M). TEVA leads profitability with a 2.9% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 42/100 (D).
CTOR
Avoid24
out of 100
Grade: F
TEVA
Hold42
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Strong operational efficiency at 27.4%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of 6.3% — below average capital efficiency
2.9% margin — thin
Premium valuation, high expectations priced in
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTOR
The strongest argument for CTOR centers on Price/Book, Debt/Equity.
Bull Case : TEVA
The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.
Bear Case : CTOR
The primary concerns for CTOR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : TEVA
The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
CTOR carries more volatility with a beta of 3.40 — expect wider price swings.
CTOR is growing revenue faster at 0.0% — sustainability is the question.
TEVA generates stronger free cash flow (121M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (42/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Oncology, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?